Autologous or homologous coagulant produced from anticoagulated whole blood

A coagulant and volumetric technology, applied in biocides, plant growth regulators, coagulation/fibrinolytic factors, etc., can solve the time-consuming problems of thrombin

Inactive Publication Date: 2008-09-03
HARVEST TECH
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Preparation of thrombin by this method is time-consuming and requires multiple steps including the need to first prepare a plasma fraction from whole blood before contacting the plasma with ethanol

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Autologous or homologous coagulant produced from anticoagulated whole blood
  • Autologous or homologous coagulant produced from anticoagulated whole blood
  • Autologous or homologous coagulant produced from anticoagulated whole blood

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Comparisons of relevant plasma protein levels in autologous thrombin and in whole blood samples were performed using radioimmunodiffusion (RID). Whole blood was collected in tubes containing ACD-mannitol anticoagulant. Anticoagulated whole blood was then incubated with 2 ml of 95% ethanol solution for 30 minutes. Afterwards in SMARTPREP TM System (Harvest Technologies, Plymouth, MA) centrifuged the mixture while preparing a platelet concentrate. The thrombin-containing supernatant was separated from pelleted cells and specific plasma components using a serum filtration system such as a serum filtration separator (eg, Fisher Brand, Fisher Scientific, Rochester, NY) or by aspirating the supernatant using a syringe.

[0056] Platelet poor plasma was prepared as follows. Whole blood from the same donor used to prepare autologous thrombin was collected into ACD anticoagulant solution (Cytosol Laboratories, Braintree, MA). Blood samples were centrifuged and aliquoted plas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A method for the preparation of a stable autologous or homologous coagulant from whole blood is disclosed. The direct precipitation of anticoagulated whole blood obviates the need for a plasma isolation step with unexpected results. The autologous or homologous coagulant produced by the method of the present invention demonstrated clotting times equivalent to commercially available bovine thrombin and human thrombin preparations, with improved kinetics of growth factor release from activated platelets over preparations of bovine thrombin.

Description

[0001] Cross References to Related Applications [0002] This application is a non-provisional application claiming priority to US Provisional Application 60 / 442,974, filed January 27, 2003, which is hereby incorporated by reference in its entirety. technical field [0003] The present invention relates to a method for the production of rapid-acting autologous or allocoagulant accelerators from anticoagulated whole blood. Background technique [0004] Thrombin derived from human or animal plasma is a potent procoagulant of blood and blood derivatives (purified fibrinogen, platelet-rich plasma (PRP), platelet concentrate (PC), platelet-poor plasma (PPP)) agent. It acts on fibrinogen, converting it into fibrin, which leads to the formation of a fibrin matrix. The clinical use of bovine thrombin (BT) as a hemostatic agent is common, although human plasma-derived thrombin is only licensed with human plasma-derived fibrin binders such as Fibrin adhesive (Baxter Corporation) i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A01N25/02A61K35/00A61K35/14A61K38/48A61P7/04C07K14/745C12N9/74G01NG01N1/00G01N33/49
CPCC12Y304/21005C07K14/745C12N9/6429Y10T436/107497A61P7/02A61P7/04G01N33/49A61K35/14G01N1/00A61K35/00
Inventor 舍温·V.·凯维舍雷尔·沙利文梅·雅各布森卢·布拉塞蒂
Owner HARVEST TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap